• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

凝血酶激活的纤维蛋白溶解抑制剂(TAFI)的晶体结构为其内在活性及TAFIa的短半衰期提供了结构基础。

The crystal structure of thrombin-activable fibrinolysis inhibitor (TAFI) provides the structural basis for its intrinsic activity and the short half-life of TAFIa.

作者信息

Anand Kanchan, Pallares Irantzu, Valnickova Zuzana, Christensen Trine, Vendrell Josep, Wendt K Ulrich, Schreuder Herman A, Enghild Jan J, Avilés Francesc X

机构信息

Sanofi-Aventis Pharma Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt am Main, Germany.

出版信息

J Biol Chem. 2008 Oct 24;283(43):29416-23. doi: 10.1074/jbc.M804003200. Epub 2008 Jul 31.

DOI:10.1074/jbc.M804003200
PMID:18669641
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2662027/
Abstract

Mature thrombin-activable fibrinolysis inhibitor (TAFIa) is a highly unstable metallocarboxypeptidase that stabilizes blood clots by clipping C-terminal lysine residues from partially degraded fibrin. In accordance with its in vitro antifibrinolytic activity, animal studies have reported that inhibition of mature TAFI aids in the prevention of thrombosis. The level of TAFI activity is stringently regulated through (i) controlled proteolytic truncation of the zymogen (TAFI), generating the mature enzyme, TAFIa, and (ii) the short half-life of TAFIa. TAFI itself exhibits an intrinsic enzymatic activity, which is likely required to provide a baseline level of antifibrinolytic activity. The novel crystal structure presented here reveals that the active site of TAFI is accessible, providing the structural explanation for the its intrinsic activity. It also supports the notion that an "instability region" exists, in agreement with site-directed mutagenesis studies. Sulfate ions, bound to this region, point toward a potential heparin-binding site and could explain how heparin stabilizes TAFIa.

摘要

成熟的凝血酶激活的纤维蛋白溶解抑制剂(TAFIa)是一种高度不稳定的金属羧肽酶,它通过从部分降解的纤维蛋白上剪切C末端赖氨酸残基来稳定血凝块。根据其体外抗纤维蛋白溶解活性,动物研究报告称,抑制成熟的TAFI有助于预防血栓形成。TAFI活性水平通过以下方式严格调控:(i)对酶原(TAFI)进行可控的蛋白水解截短,生成成熟酶TAFIa;(ii)TAFIa的半衰期较短。TAFI本身具有内在酶活性,这可能是提供抗纤维蛋白溶解活性基线水平所必需的。此处呈现的新晶体结构表明TAFI的活性位点是可及的,为其内在活性提供了结构解释。这也支持了“不稳定区域”存在的观点,这与定点诱变研究一致。与该区域结合的硫酸根离子指向一个潜在的肝素结合位点,这可以解释肝素如何稳定TAFIa。

相似文献

1
The crystal structure of thrombin-activable fibrinolysis inhibitor (TAFI) provides the structural basis for its intrinsic activity and the short half-life of TAFIa.凝血酶激活的纤维蛋白溶解抑制剂(TAFI)的晶体结构为其内在活性及TAFIa的短半衰期提供了结构基础。
J Biol Chem. 2008 Oct 24;283(43):29416-23. doi: 10.1074/jbc.M804003200. Epub 2008 Jul 31.
2
Generation of a stable activated thrombin activable fibrinolysis inhibitor variant.稳定的活化凝血酶激活的纤溶抑制物变体的产生。
J Biol Chem. 2006 Jun 9;281(23):15878-83. doi: 10.1074/jbc.M509839200. Epub 2006 Apr 4.
3
Structure of activated thrombin-activatable fibrinolysis inhibitor, a molecular link between coagulation and fibrinolysis.活化的凝血酶激活的纤溶抑制物的结构,凝血与纤溶之间的分子联系。
Mol Cell. 2008 Aug 22;31(4):598-606. doi: 10.1016/j.molcel.2008.05.031.
4
Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis.凝血酶可激活的纤维蛋白溶解抑制剂酶原在纤维蛋白溶解的减弱过程中不起重要作用。
J Biol Chem. 2008 Apr 4;283(14):8863-7. doi: 10.1074/jbc.M800127200. Epub 2008 Feb 5.
5
Generation and characterization of a highly stable form of activated thrombin-activable fibrinolysis inhibitor.高稳定性活化凝血酶激活的纤溶抑制物形式的产生与特性研究
J Biol Chem. 2004 Feb 20;279(8):6620-8. doi: 10.1074/jbc.M307337200. Epub 2003 Dec 4.
6
Role of isoleucine residues 182 and 183 in thrombin-activatable fibrinolysis inhibitor.异亮氨酸残基182和183在凝血酶可激活纤维蛋白溶解抑制剂中的作用。
J Thromb Haemost. 2005 Jun;3(6):1293-300. doi: 10.1111/j.1538-7836.2005.01322.x.
7
Comparative evaluation of stable TAFIa variants: importance of alpha-helix 9 and beta-sheet 11 for TAFIa (in)stability.稳定的凝血酶激活的纤溶抑制物(TAFIa)变体的比较评估:α-螺旋9和β-折叠11对TAFIa(不)稳定性的重要性
J Thromb Haemost. 2007 Oct;5(10):2105-12. doi: 10.1111/j.1538-7836.2007.02720.x. Epub 2007 Jul 31.
8
Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme.凝血酶激活的纤溶抑制因子(TAFI)的两种天然存在变体(苏氨酸-325和异亮氨酸-325)在该酶的热稳定性和抗纤溶活性方面存在显著差异。
J Biol Chem. 2002 Jan 11;277(2):1021-30. doi: 10.1074/jbc.M104444200. Epub 2001 Oct 29.
9
Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity.阐明两种纳米抗体抑制凝血酶激活的纤溶抑制物激活和激活的凝血酶激活的纤溶抑制物活性的分子机制。
J Thromb Haemost. 2016 Aug;14(8):1629-38. doi: 10.1111/jth.13381. Epub 2016 Jul 27.
10
Crystal structures of TAFI elucidate the inactivation mechanism of activated TAFI: a novel mechanism for enzyme autoregulation.凝血酶激活的纤溶抑制因子(TAFI)的晶体结构阐明了活化TAFI的失活机制:一种酶自我调节的新机制。
Blood. 2008 Oct 1;112(7):2803-9. doi: 10.1182/blood-2008-03-146001. Epub 2008 Jun 17.

引用本文的文献

1
Identification of heparin interaction sites on thrombin-activatable fibrinolysis inhibitor that modulate plasmin-mediated activation, thermal stability, and antifibrinolytic potential.鉴定凝血酶激活的纤维蛋白溶解抑制剂上的肝素相互作用位点,这些位点可调节纤溶酶介导的激活、热稳定性和抗纤维蛋白溶解潜力。
Res Pract Thromb Haemost. 2024 May 27;8(4):102459. doi: 10.1016/j.rpth.2024.102459. eCollection 2024 May.
2
Losing the forest for the trees: The complexities of fibrinolysis will never be explained with one variable alone.只见树木,不见森林:纤溶的复杂性永远不可能仅用一个变量来解释。
J Trauma Acute Care Surg. 2024 Jan 1;96(1):e5-e7. doi: 10.1097/TA.0000000000004137. Epub 2023 Oct 3.
3
Enhanced Production of ECM Proteins for Pharmaceutical Applications Using Mammalian Cells and Sodium Heparin Supplementation.使用哺乳动物细胞和补充肝素钠提高用于制药应用的细胞外基质蛋白产量。
Pharmaceutics. 2022 Oct 8;14(10):2138. doi: 10.3390/pharmaceutics14102138.
4
Isolation, Co-Crystallization and Structure-Based Characterization of Anabaenopeptins as Highly Potent Inhibitors of Activated Thrombin Activatable Fibrinolysis Inhibitor (TAFIa).作为高度有效的活化凝血酶可激活纤溶抑制物(TAFIa)抑制剂,从鱼腥藻肽中分离、共结晶和基于结构的表征。
Sci Rep. 2016 Sep 8;6:32958. doi: 10.1038/srep32958.
5
Flexibility of the thrombin-activatable fibrinolysis inhibitor pro-domain enables productive binding of protein substrates.凝血酶激活的纤溶抑制物前肽结构域的柔韧性使其能够与蛋白质底物进行有效结合。
J Biol Chem. 2010 Dec 3;285(49):38243-50. doi: 10.1074/jbc.M110.150342. Epub 2010 Sep 29.
6
Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?羧肽酶 U(TAFIa):纤维蛋白溶解治疗的新靶点?
J Thromb Haemost. 2009 Dec;7(12):1962-71. doi: 10.1111/j.1538-7836.2009.03596.x. Epub 2009 Aug 28.
7
Biochemical characterization of bovine plasma thrombin-activatable fibrinolysis inhibitor (TAFI).牛血浆凝血酶激活的纤溶抑制物(TAFI)的生化特性
BMC Biochem. 2009 May 5;10:13. doi: 10.1186/1471-2091-10-13.
8
The roles of selected arginine and lysine residues of TAFI (Pro-CPU) in its activation to TAFIa by the thrombin-thrombomodulin complex.凝血酶-血栓调节蛋白复合物将凝血酶激活因子前体(Pro-CPU)激活为凝血酶激活因子(TAFIa)过程中特定精氨酸和赖氨酸残基的作用。
J Biol Chem. 2009 Mar 13;284(11):7059-67. doi: 10.1074/jbc.M804745200. Epub 2008 Dec 12.

本文引用的文献

1
Comparative evaluation of stable TAFIa variants: importance of alpha-helix 9 and beta-sheet 11 for TAFIa (in)stability.稳定的凝血酶激活的纤溶抑制物(TAFIa)变体的比较评估:α-螺旋9和β-折叠11对TAFIa(不)稳定性的重要性
J Thromb Haemost. 2007 Oct;5(10):2105-12. doi: 10.1111/j.1538-7836.2007.02720.x. Epub 2007 Jul 31.
2
MolProbity: all-atom contacts and structure validation for proteins and nucleic acids.MolProbity:蛋白质和核酸的全原子接触与结构验证
Nucleic Acids Res. 2007 Jul;35(Web Server issue):W375-83. doi: 10.1093/nar/gkm216. Epub 2007 Apr 22.
3
Metallocarboxypeptidases: emerging drug targets in biomedicine.金属羧肽酶:生物医学中新兴的药物靶点。
Curr Pharm Des. 2007;13(4):349-66. doi: 10.2174/138161207780162980.
4
Thrombin-activable fibrinolysis inhibitor (TAFI) zymogen is an active carboxypeptidase.凝血酶激活的纤维蛋白溶解抑制剂(TAFI)酶原是一种活性羧肽酶。
J Biol Chem. 2007 Feb 2;282(5):3066-76. doi: 10.1074/jbc.M606559200. Epub 2006 Nov 30.
5
A role for procarboxypepidase U (TAFI) in thrombosis.前羧肽酶U(TAFI)在血栓形成中的作用。
Front Biosci. 2007 Jan 1;12:1973-87. doi: 10.2741/2203.
6
The intrinsic enzymatic activity of plasma procarboxypeptidase U (TAFI) can interfere with plasma carboxypeptidase N assays.血浆前羧肽酶U(TAFI)的内在酶活性会干扰血浆羧肽酶N检测。
Anal Biochem. 2006 Sep 1;356(1):157-9. doi: 10.1016/j.ab.2006.05.020. Epub 2006 Jun 5.
7
Generation of a stable activated thrombin activable fibrinolysis inhibitor variant.稳定的活化凝血酶激活的纤溶抑制物变体的产生。
J Biol Chem. 2006 Jun 9;281(23):15878-83. doi: 10.1074/jbc.M509839200. Epub 2006 Apr 4.
8
Post-translational modifications of human thrombin-activatable fibrinolysis inhibitor (TAFI): evidence for a large shift in the isoelectric point and reduced solubility upon activation.人凝血酶激活的纤维蛋白溶解抑制剂(TAFI)的翻译后修饰:激活后等电点大幅偏移及溶解度降低的证据。
Biochemistry. 2006 Feb 7;45(5):1525-35. doi: 10.1021/bi051956v.
9
Limited mutagenesis increases the stability of human carboxypeptidase U (TAFIa) and demonstrates the importance of CPU stability over proCPU concentration in down-regulating fibrinolysis.有限诱变增加了人羧肽酶U(TAFIa)的稳定性,并证明了在下调纤维蛋白溶解过程中,CPU稳定性比proCPU浓度更为重要。
FEBS J. 2006 Feb;273(4):778-92. doi: 10.1111/j.1742-4658.2006.05110.x.
10
MEROPS: the peptidase database.MEROPS:肽酶数据库。
Nucleic Acids Res. 2006 Jan 1;34(Database issue):D270-2. doi: 10.1093/nar/gkj089.